There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle room when companies pay to sponsor online search results.

Though Novo Nordisk had a first-mover advantage in the GLP-1 market, Eli Lilly is catching up. Lilly's recent clinical progress sets it up for another critical approval. The company has fantastic ...

Just when you thought it was safe to turn on the television… a TV show not known for horror takes a turn for the nightmarish. As you’ll see below, horror stories have invaded procedural, sci-fi, ...

DANVILLE — Go see a haunted circus extravaganza complete with an 8-foot-tall ringmaster, a bearded lady, and even some ‘contortionists’ in the yard on North Vermilion Street. Erin Leverenz and her ...

Microdosing GLP-1 weight loss drugs like semaglutide is trendy, with supporters touting benefits such as lower costs and potentially fewer side effects. But some doctors are skeptical, calling it ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ...

In case anyone forgot amid Mariners fever, Seattle has another high-stakes contest this fall. The team’s owners certainly haven’t. The two races – one for the pennant, one for the mayor’s office – ...